Protection of neurons derived from human neural progenitor cells by veratridine.

PDF's targeted PubMed search provides you with access to journal articles from the last 90 days that may be pertinent to Parkinson's disease research. 

Not what you're looking for? Do you need informational publications about Parkinson's targeted for people living with Parkinson's, caregivers and family members?  Please browse PDF's educational materials and programs - which are all available electronically or in print.  Order for yourself, a loved one or in bulk for your patients or support group.

Neuroreport 2009 Jul;

Authors: Peter Morgan, Stefanie Ortinau, Jana Frahm, Norman Krüger, Arndt Rolfs, Moritz Frech

Albrecht-Kossel-Institute for Neuroregeneration (AKos), Centre for Mental Health Diseases, University of Rostock, Gehlsheimer Strasse, Rostock, Germany.

The survival of developing dopaminergic neurons has been shown to be modulated by voltage-dependent mechanisms. Manipulation of these mechanisms in human neural progenitor cell cultures could improve the survival of immature dopaminergic neurons, and therefore aid research into pharmacological and cell replacement therapies for Parkinson's disease. Here, we examined the effect of the Na channel agonist veratridine on the human fetal neural progenitor ReNcell VM cell line. Neuronal differentiation was determined by immunocytochemistry, whereas patch clamp recordings showed the expression of functional voltage-gated sodium channels. Our results show that veratridine is neuroprotective in human fetal neural progenitor cells, which may benefit studies investigating neuronal development by reducing premature death amongst developing neurons.

PMID: 19617853 [PubMed - as supplied by publisher]

See More

Back to PubMed Articles